Table 1.

Demographic data of recruited patients

Mets (n = 43)BPLAE (n = 33)MPM (n = 96)AE (n = 112)
Age, y (mean ± SD)66.1 ± 11.262.2 ± 10.565 ± 9.763 ± 6.8
Male gender, n (%)24 (56)32 (97)78 (81)95 (84)
Mode of diagnosis, n (%)
    Blind pleural biopsy2 (4.7)1 (1)NA
    Thoracoscopy29 (67.4)22 (66.7)60 (62.5)
    Surgery (VATS or open surgery)8 (18.6)11 (33.3)31 (32.3)
    Guided biopsy (CT or US)4 (9.3)4 (4.1)
Confirmed asbestos exposure, n (%)15 (34.9)28 (84.8)82 (85.4)112 (100)
Survival, median (95% CI) mos*9 (6-12)14 (10-18)NA
Staging (IMIG classification)
    Stage INANA11NA
    Stage II21
    Stage III32
    Stage IV19
  • Abbreviations: VATS, video-assisted thoracoscopic surgery; CT, chest computed tomography scan; US, ultrasound; IMIG, International Mesothelioma Interest Group; NA, not applicable.

  • * Median survival was not calculated for the BPLAE group; only three (9.1%) deaths were noted in this group, one due to one bronchial adenocarcinoma and two nonneoplastic, non-asbestos–related deaths.

  • Complete tumor-node-metastasis staging was available for 83 patients.